Scancell founder says the company is ready to commercialise novel medicines to counteract cancer. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAllergy Thera. Share News (AGY)

Share Price Information for Allergy Thera. (AGY)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 5.25
Bid: 5.00
Ask: 5.50
Change: 0.00 (0.00%)
Spread: 0.50 (10.00%)
Open: 5.25
High: 5.25
Low: 5.00
Prev. Close: 5.25
AGY Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LONDON MARKET CLOSE: FTSE 100 edges higher and New York stocks jump

Thu, 29th Dec 2022 16:52

(Alliance News) - London's FTSE 100 achieved a solid, though unspectacular, gain during the final full trading of the year on Thursday, with investors mindful of what an ease of Covid-19 curbs in China could mean for global inflation.

The FTSE 100 index ended up 15.53 points, or 0.2%, at 7,512.72. The FTSE 250 rose 110.95 points, or 0.6% at 18,996.45, and the AIM All-Share added 4.17 points, or 0.5%, at 836.45.

The Cboe UK 100 rose 0.1% at 750.88, the Cboe UK 250 added 0.6% at 16,459.77, and the Cboe Small Companies climbed 0.6% at 13,188.32.

The gains for London-listed large-caps were eclipsed by peers on the old continent and across the Atlantic.

In Europe, the CAC 40 index in Paris closed up 1.0%, while the DAX 40 in Frankfurt jumped 1.1%.

In New York, the Dow Jones Industrial Average was up 1.0% at the time of the closing bell in London, the S&P 500 was up 1.6% and the Nasdaq Composite jumped 2.4%.

Stocks in Paris, Frankfurt and New York had struggled on Wednesday.

Oanda analyst Craig Erlam commented: "We continue to drift into year-end with investors having little to cling onto that's going to drive markets one way or another. That is so often the case this time of year and while 2022 could have been different, given how chaotic the rest of the year has been, it has proven to not be the case. Investors are going into 2023 with a cautious mindset, prepared for more rate hikes, and expecting recessions around the globe. The bar is low but arguably reasonably so."

Investors worldwide initially welcomed the relaxation of Covid-19 restrictions in China, but they are now becoming increasingly concerned about the ramifications of the reopening of the Chinese economy for global supply chains and inflation.

Some nations have imposed restrictions on Chinese arrivals. The US and a number of other countries announced they would require negative Covid tests for all travellers from mainland China, though the UK so far has not.

However, the UK government appeared to backtrack on its suggestion that travellers from China will not be screened for Covid after critics, including two former health ministers, called for testing to be introduced.

Defence Secretary Ben Wallace said on Thursday that the possibility of imposing restrictions on visitors from the East Asian country was "under review".

It comes after former health ministers James Bethell and Steve Brine were among those to place pressure on the government following its assertion that there were "no plans" to introduce tests for China arrivals.

London-listed miners faced selling pressure on Thursday, having initially cheered the news out of China on Wednesday. China is a major buyer of minerals.

Anglo American fell 1.0%, while Antofagasta lost 2.1%.

Also hitting Antofagasta's stock, the miner reported that access to its Los Pelambres operation in Chile is being blocked by a group of people, affecting the transport of critical supplies and personnel to the mine site.

Antofagasta explained that the group is requesting compensation to clear access but added that, to date, there has been no material impact on production.

At the other end of the large-cap index, Scottish Mortgage Investment Trust rose 3.7%. The investor holds stakes in various US tech shares, which traded higher on Thursday.

Ferrexpo extended declines, losing 3.0% after a 4.9% drop on Wednesday. The iron ore pellet producer noted that Non-Executive Director Kostyantin Zhevago, who owns over 50% of the firm, has been detained by the French authorities.

Ferrexpo said that it believes this is for matters unrelated to the firm, but said it would week to clarify the situation and update as appropriate.

Applied Graphene extended gains. The AIM listing added a 34% rise to its 20% share price hike from Wednesday.

On Wednesday, it said it received non-binding indicative proposals for its sale or the sale of its main operating subsidiary.

The Cleveland, England-based graphene materials maker said it is in discussions with the parties involved and expects final proposals in early January. After this, the board would then select a preferred bidder to progress with. Applied added that there can be no certainty any final proposals will be made, nor the terms of any proposals made.

Allergy Therapeutics plunged 56% after it said its shares will be suspended from trading next week, due to delays in completing the audit of its annual results.

Back in September, Allergy Therapeutics announced its unaudited preliminary results for the financial year that ended June 30. It sunk to a pretax loss of GBP12.7 million from a profit of GBP3.7 million the year prior. Revenue dropped to GBP72.8 million from GBP84.3 million.

"It is not aware of any material change that will be required to be made to the results, and it is actively working to finalise the audit and publication of its annual report and accounts," Allergy Therapeutics said.

The pound was quoted at USD1.2057 at the time of the London equities close on Thursday, up compared to USD1.2029 at the close on Wednesday. The euro stood at USD1.0661, higher against USD1.0617. Against the yen, the dollar was trading at JPY133.31, lower compared to JPY134.23.

Brent oil was quoted at USD82.78 a barrel in London on Thursday, down slightly from USD82.87 late Wednesday. Gold was quoted at USD1,811.91 an ounce, higher against USD1,801.04.

Friday's economic calendar has a UK Nationwide house price index reading at 0700 GMT. Financial markets in London will close early at 1230 GMT on Friday.

By Eric Cunha, Alliance News news editor

Comments and questions to newsroom@alliancenews.com

Copyright 2022 Alliance News Ltd. All Rights Reserved.

More News
27 Nov 2018 13:12

Allergy Therapeutics Continues To Perform Well, Revenue Up "Strongly"

LONDON (Alliance News) - Allergy Therapeutics PLC said Tuesday it has continued to perform well, with revenue up "strongly" from the prior year and sales in line with market financial to

Read more
27 Nov 2018 10:05

Allergy Therapeutics boosted by strong German performance

(Sharecast News) - Biotechnology company Allergy Therapeutics has seen revenues increase throughout the first half of its trading year thanks to an improved market share for its allergy vaccines on the continent.

Read more
23 Oct 2018 16:11

BlackRock Lowers Allergy Therapeutics Stake Below Threshold (ALLISS)

LONDON (Alliance News) - Allergy Therapeutics PLC said Tuesday that BlackRock Inc lowered its stake in the company to below the 5% threshold.Prior to the deal, BlackRock held a 5.1% in the

Read more
26 Sep 2018 12:42

Allergy Therapeutics Interim Loss Widens But Germany Pushes Revenue Up

LONDON (Alliance News) - Allergy Therapeutics PLC on Wednesday said its loss widened in the first half of 2018, but revenue rose on strong performance in Germany and a strengthening of the company

Read more
19 Jul 2018 11:08

Allergy Therapeutics To Raise GBP11 Million Via Share Issue (ALLISS)

LONDON (Alliance News) - Allergy Therapeutics PLC said Thursday that it will raise up to GBP10.6 million via placing and subscription.The pharmaceutical company focused on allergy vaccines

Read more
29 May 2018 11:19

Allergy Therapeutics Reveals Good Results From Dust Mite Allergy Tests

LONDON (Alliance News) - Biotechnology firm Allergy Therapeutics PLC said it will present positive new data on its dust mite allergy treatment at a congress in Germany on Tuesday.Allergy is

Read more
21 May 2018 11:49

Allergy Therapeutics Reports Positive Results From Grass Pollen Study

LONDON (Alliance News) - Allergy Therapeutics PLC said Monday it saw positive results from its grass pollen allergy treatment phase II dose ranging study as it prepares to commence in phase III it

Read more
14 May 2018 12:24

Allergy Therapeutics Gets Positive Indications In Latest MCT Study

LONDON (Alliance News) - Biotechnology firm Allergy Therapeutics PLC on Monday said it has received positive new data in a study investigating its microcrystalline tyrosine-based results, it said,

Read more
16 Mar 2018 17:30

DIRECTOR DEALINGS: Allergy Therapeutics Non-Executive Lifts Stake

LONDON (Alliance News) - Pharmaceutical company Allergy Therapeutics PLC said Friday Non-Executive Director Tunde Otulana acquired shares on Thursday.Otulana acquired a

Read more
7 Mar 2018 13:42

Allergy Therapeutics Profit Falls On Costs As Pivotal Year Looms

LONDON (Alliance News) - Allergy Therapeutics PLC said Wednesday half year profit fell due to higher research and development costs, as the company prepares for 2018 clinical

Read more
14 Feb 2017 14:46

Allergy Therapeutics gets trial go-ahead in Spain

(ShareCast News) - Specialty pharmaceutical company Allergy Therapeutics announced on Tuesday that its Phase I clinical study investigating the safety and tolerability of Acarovac MPL received 'Clinical Trial Application' approval in Spain. The AIM-traded firm said it now expected the formulation to

Read more
14 Feb 2017 08:49

Allergy Therapeutics' House-Dust Mite Allergy Vaccine Trial Approved

Read more
2 Nov 2016 09:41

New broad patent strengthens Allergy Therapeutics portfolio

(ShareCast News) - Vaccine-focused pharmaceutical company Allergy Therapeutics announced on Wednesday that the European Patent Office has granted a broad technology patent relating to the its unique microcrystalline tyrosine depot adjuvant manufacturing process. The AIM-traded firm said the patent c

Read more
2 Nov 2016 09:29

Allergy Therapeutics Granted EU Patent For Microcrystalline Tyrosine

Read more
10 Oct 2016 11:59

Allergy Therapeutics examines potential of adjuvant portfolio

(ShareCast News) - Allergy Therapeutics will look into potential wider applications for its adjuvant technology after recent clinical research produced encouraging indications about both allergy vaccination and infectious disease applications. Microcrystalline tyrosine (MCT), an aluminium-free depot

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.